132 related articles for article (PubMed ID: 15541482)
41. [A three-year experience with use of mabthera (rituximab) in treatment of indolent non-Hodgkin's disease refractory to standard chemotherapy].
Korolenko VO; Gershanovich ML; Tikhonova VV
Vopr Onkol; 2004; 50(4):421-5. PubMed ID: 15605764
[No Abstract] [Full Text] [Related]
42. Rituximab for the treatment of CD20-positive peripheral T-cell lymphoma, unspecified.
Hirata Y; Yokote T; Kobayashi K; Nakayama S; Miyoshi T; Akioka T; Hara S; Tsuji M; Takubo T; Hanafusa T
Leuk Res; 2009 Jun; 33(6):e13-6. PubMed ID: 18995899
[No Abstract] [Full Text] [Related]
43. Rapid infusion rituximab changing practice for patient care.
Al Zahrani A; Ibrahim N; Al Eid A
J Oncol Pharm Pract; 2009 Sep; 15(3):183-6. PubMed ID: 19171551
[TBL] [Abstract][Full Text] [Related]
44. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group.
Witzig TE; Vukov AM; Habermann TM; Geyer S; Kurtin PJ; Friedenberg WR; White WL; Chalchal HI; Flynn PJ; Fitch TR; Welker DA
J Clin Oncol; 2005 Feb; 23(6):1103-8. PubMed ID: 15657404
[TBL] [Abstract][Full Text] [Related]
45. Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma.
Martin P; Furman RR; Ruan J; Elstrom R; Barrientos J; Niesvizky R; Coleman M; Leonard JP
Semin Hematol; 2008 Apr; 45(2):126-32. PubMed ID: 18381108
[TBL] [Abstract][Full Text] [Related]
46. Elevation of activated platelet-dependent chemokines in patients with anti-CD20 monoclonal antibody (rituximab)-treated non-Hodgkin's lymphoma.
Nomura S; Ishii K; Kamitsuji Y; Uoshima N; Ishikawa E; Kitayama H; Hayashi K
Clin Appl Thromb Hemost; 2007 Apr; 13(2):206-12. PubMed ID: 17456632
[TBL] [Abstract][Full Text] [Related]
47. A case of non-Hodgkin's lymphoma-associated pemphigus foliaceus and use of rituximab for treatment.
Prodanovic EM; Korman NJ
J Dermatolog Treat; 2008; 19(6):1-3. PubMed ID: 18720187
[TBL] [Abstract][Full Text] [Related]
48. [Rituximab in the treatment of B-cell non-Hodgkin lymphoma].
Mitrović Z; Aurer I
Lijec Vjesn; 2006; 128(1-2):36-42. PubMed ID: 16640226
[TBL] [Abstract][Full Text] [Related]
49. Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation.
Nishio M; Fujimoto K; Yamamoto S; Endo T; Sakai T; Obara M; Kumano K; Yamaguchi K; Takeda Y; Goto H; Sato N; Koizumi K; Mukai M; Koike T
Br J Haematol; 2007 May; 137(4):349-54. PubMed ID: 17456057
[TBL] [Abstract][Full Text] [Related]
50. Primary conjunctival follicular lymphoma treated with the anti-CD20 antibody rituximab and low-dose involved-field radiotherapy.
Takahira M; Okumura H; Minato H; Urushisaki N; Sakurai M; Sugiyama K
Jpn J Ophthalmol; 2007; 51(2):149-51. PubMed ID: 17401629
[No Abstract] [Full Text] [Related]
51. Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas.
Pagel JM; Laugen C; Bonham L; Hackman RC; Hockenbery DM; Bhatt R; Hollenback D; Carew H; Singer JW; Press OW
Clin Cancer Res; 2005 Jul; 11(13):4857-66. PubMed ID: 16000584
[TBL] [Abstract][Full Text] [Related]
52. [Rituximab resistance in B-cell lymphoma and its elimination].
Hatake K; Terui Y
Gan To Kagaku Ryoho; 2009 Apr; 36(4):548-51. PubMed ID: 19381025
[TBL] [Abstract][Full Text] [Related]
53. [The disappearance of CD20 positive lymphocytes in the pleural effusion after intrapleural application of rituximab].
Kalac M; Kolonić SO; Kardum-Skelin I; Planinc-Peraica A; Siftar Z; Jaksić B
Acta Med Croatica; 2007 Sep; 61(4):425-7. PubMed ID: 18044481
[TBL] [Abstract][Full Text] [Related]
54. In focus: ECOG 4402: Rituximab Extended Schedule or Retreatment Trial (RESORT).
Clin Adv Hematol Oncol; 2004 Mar; 2(3):152. PubMed ID: 16166942
[No Abstract] [Full Text] [Related]
55. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Thomas DA; Faderl S; O'Brien S; Bueso-Ramos C; Cortes J; Garcia-Manero G; Giles FJ; Verstovsek S; Wierda WG; Pierce SA; Shan J; Brandt M; Hagemeister FB; Keating MJ; Cabanillas F; Kantarjian H
Cancer; 2006 Apr; 106(7):1569-80. PubMed ID: 16502413
[TBL] [Abstract][Full Text] [Related]
56. Use of rituximab in combination with conventional chemotherapy for the treatment of non-Hodgkin's lymphoma of the head and neck.
Manolopoulos L; Gomatos IP; Leandros E; Alevizos L; Georgiou N; Giotakis J; Ferekidis E
In Vivo; 2009; 23(3):475-8. PubMed ID: 19454517
[TBL] [Abstract][Full Text] [Related]
57. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab.
Kyrtsonis MC; Siakantaris MP; Kalpadakis C; Dimopoulou MN; Vassilakopoulos TP; Kontopidou FN; Antoniou C; Korkolopoulou P; Panayiotidis P; Pangalis GA
Eur J Haematol; 2006 Oct; 77(4):300-3. PubMed ID: 16856917
[TBL] [Abstract][Full Text] [Related]
58. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.
Friedberg JW; Cohen P; Chen L; Robinson KS; Forero-Torres A; La Casce AS; Fayad LE; Bessudo A; Camacho ES; Williams ME; van der Jagt RH; Oliver JW; Cheson BD
J Clin Oncol; 2008 Jan; 26(2):204-10. PubMed ID: 18182663
[TBL] [Abstract][Full Text] [Related]
59. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
Aydin S; Dührsen U; Nückel H
Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
[TBL] [Abstract][Full Text] [Related]
60. Reply to 'Rituximab in CD20 positive multiple myeloma' by P Moreau et al.
Greipp PT; Kapoor P; Morice WG; Witzig TE; Greipp PR
Leukemia; 2008 Jan; 22(1):214-5. PubMed ID: 17928885
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]